Table 4.

Regression Models of Change Over Time in Buprenorphine Prescribing and Completion of Integrated Support for MOUD Program Aims, 2022-2023 (N = 15)

OutcomeBSEP Valuea
No. of active buprenorphine prescriptions
Time
    0 monthsrefref<.001
    6 months0.840.21<.001
    13 months1.670.19<.001
Specialty
    Non–family medicinerefref.92
    Family medicine−0.121.21
Organization type
    Clinician-ownedrefref.83
    FQHC0.280.98
    Hospital or health system owned0.921.05
    Other−0.131.58
Core aim 1 completion
Time
    0 monthsrefref<.001
    3 months0.280.06<.001
    6 months0.400.06<.001
    9 months0.490.06<.001
    13 months0.530.06<.001
Specialty
    Non–family medicinerefref.18
    Family medicine−0.110.08
Organization type
    Clinician-ownedrefref.95
    FQHC0.010.06
    Hospital or health system owned−0.030.07
    Other−0.030.10
Core aim 2 completion
Time
    0 monthsrefref<.001
    3 months0.200.05<.001
    6 months0.340.05<.001
    9 months0.500.05<.001
    13 months0.610.05<.001
Specialty
    Non–family medicinerefref.99
    Family medicine0.000.07
Organization type
    Clinician-ownedrefref.56
    FQHC−0.030.06
    Hospital or health system owned−0.080.06
    Other−0.090.09
Core aim 3 completion
Time
    0 monthsrefref<.001
    3 months0.160.06.013
    6 months0.290.06<.001
    9 months0.590.06<.001
    13 months0.650.06<.001
Specialty
    Non–family medicinerefref.67
    Family medicine0.030.07
Organization type
    Clinician-ownedrefref.14
    FQHC−0.120.06
    Hospital or health system owned0.000.06
    Other0.030.10
  • FQHC = Federally Qualified Health Center; ref = reference group; SE = standard error.

  • a Outcomes from multiple regressions were adjusted for multiple comparisons using Bonferroni’s method; P values <.013 were considered statistically significant.